
Translation and early phase research at MHH

ZKS & Early Clinical Trial Unit (ECTU)


Prof. Dr. med. Christoph Schindler ZKS – Center for Clinical Trials, OE 8660 & 8661 Feodor-Lynen-Straße 15 30625 Hannover

Hannover Medical School









Translational Medicine

- is a way to overcome the extreme specialization
- implies evolution in thinking and organizing research centers, especially also *university students*, in order to create a continuous flow of knowledge and bidirectional operation that goes *from the laboratory to the bedside*.
- Root is the collaboration between various professionals, each skilled and specialized in their field, knowledge of which can certainly be transformed into an added value as well as economic ensuring concrete results in even shorter time.

Translational Medicine @ UniSa, - ISSN 2239-9747 2013, 5(3): 5-6







Transl Res. 2012 June ; 159(6): 430–453. doi:10.1016/j.trsl.2011.12.009.

Translational research in infectious disease: current paradigms and challenges ahead

Judith M. Fontana, PhD^a, Elizabeth Alexander, MD^b, and Mirella Salvatore, MD^{a,b} ^aDepartment of Public Health, Weill Cornell Medical College, New York, NY 10065. ^bDepartment of Medicine, Weill Cornell Medical College, New York, NY 10065.

Bridging the gaps:

"Turning scientific *promise* into clinical *practice*."



"Interdisciplinarity"

Basic Scientists and researchers, regulatory experts, project managers, physicians, clinician scientists, etc. ...


Mills IG and Sykes RB: Taking risks with translational research. *Sci Transl Med.* **2**, 24-10 2010



Hannover Medical School



Requirements for Translational Medicine



Translation in University Medicine in Germany

- 1) Research possibility:
- 2) Patient access:
- 3) Infrastructure:

- **3.1** billion state contribution (LZB), **1.5** third p.
- 1.76 million in patients, 6.3 mio outpatients
- variable at MHH: CRC Hannover (ECTU)





Translation in University Medicine

- 170.000 employees in University Medicine work in institutions with an annual turnover of 15 – 17 billion Euro (source: German Federal Office of Statistics)
- The education of young academics takes exclusively place in University Medicine
- Biomedical cutting edge research is *impossible* without University Medicine (e.g. Excellence Initiative)



German University Medicine is the *perfect place* to **conduct Translational Medicine Projects**, because all necessary requirements are fulfilled !





German Science Council – recommendations infrastructure

- All university hospitals should continuously provide basic infrastructure for clinical trials (expert advise, administrative support and infrastructure).
- Establishment of comprehensive **Clinical Trial Units** as basic infrastructure
- Permanent funding of both *infrastructure* and *specialized staff* recommended (by german federal states or universities).
- **Reservation** of clearly defined independent spacial capacities *only* and *exclusively*

for early phase proof of concept trials.

Strategiepapier für den Aufbau von Forschungsnetzwerken für klinische Studien in Deutschland. AG Infrastruktur in den Lebenswissenschaften des Forums Gesundheitsforschung, an BMBF 9.8.18

Wissenschaftsrat Empfehlungen Drs. 7301-18 ; Hannover 19.10.2018





Clinical Research Center (CRC) Hannover

Concept – Translational Infrastructure

Partner Alliance consists of MHH University Medicine and two Life Science research organisations:

- Hannover Medical School (MHH)
- Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM)
- Helmholtz-Center for Infectious Diseases (HZI)

Purpose:

- Provide Infrastructure for early clinical studies (MHH and ITEM); unique QMS
 - Phase I: First-in-man
 - Phase IIa: Proof-of-concept
- Infrastructure for National Cohort (HZI)
- Hannover Unified Biobank HUB (MHH)







Clinical Research Center (CRC) Hannover Infrastructure for Early Phase Research

- ✓ **Research Ward 1:** Phase I unit with 20 intermediate care beds (CV-monitoring)
- ✓ **Research Ward 2:** comfortable accomodation for 20 study participants as inpatients
- Outpatient area for physical examination, medical and social interviews and for physician – patient interaction
- ✓ Functional area for special diagnostic procedures (eg. ECG, Echo, lung function, endoscopy (gastro-, colonoscopy, broncoscopy, body plethysmography)
- ✓ CRC Imaging Unit (MRI for Clinical Research Purpose), 1.5 T MRI, 3T MRI
- ✓ Central Biobanking for research samples according to state of the art standards
- ✓ GMP-certified biomarker laboratory





Early Clinical Trial Unit (ECTU) at CRC



Photos: Phase I Unit – MHH Medical Team ECTU





Clinical Research Center (CRC) Hannover Special Infrastructure Ophthalmology and ENT








Clinical Research Center (CRC) Hannover

Interdisciplinary Collaboration at MHH in the early phase



- Medical and Scientific expertise of clinical department (PI)
- Responsibility for Medicine and Science
- Expert staff (e.g. specialized nurse)
- Recruiting of specific study populations

- Clinical Trials Operation / GCP expertise / Co-PI
- Responsibility for Quality Assurance (SOP system)
- Study Conduction (e.g. PK sampling) and coordination
- Study Team (Study Nurse, documentalist), study treatment and supervision






Hannover Unified Biobank (HUB)

- Central Biobank of MHH
- Highest quality standards
- Standardized processes and automation
- Storage in nitrogen tanks at 80 degree Celsius
- Tubes connected via Data
 Warehouse with clinical data

29 Third party projects in 2022	3.205232 Tubes stored
232 projects	ISO 9001 Certified since 2015









"Die moderne Biobank-Infrastruktur und die Professionalität, Flexibilität und hohe Effektivität des Teams der Hannover Unified Biobank ermöglichen es uns, Bioproben von gleichbleibend hoher Qualität für unsere Forschungsprojekte zu nutzen. Dies ist ein wichtiger Grundstein für unsere Erfolge in der biomedizinischen Forschung."

PD Dr. Anke Kraft


Klinik für Gastroenterologie, Hepatologie und Endokrinologie, Medizinische Hochschule Hannover

Prof. Dr. Markus Cornberg Zentrum für Individualisierte Infektionsmedizin (CiiM), c/o Clinical Research Center Hannover









Research Foci at MHH







Clinical Research Center (CRC) Hannover Collaboration with MHH Clinics and trial indications

- ✓ Immunology and Vaccination
- ✓ Neurology
- ✓ Psychiatry (Tourette, ADHS)
- ✓ Ophthalmology
- ✓ Ear Nose and Throat (ENT)

Early Clinical Trial Unit:

Professional staff: 14




70 – 80 patient contacts/month in complex early phase trials (ECTU only)

Patient contacts 2022 (CRC in total): 6703 patient contacts, 4202 for MHH





Sucsess in translation not ex nihilo



Clin Neuroradiol DOI 10.1007/s00062-015-0457-0

REVIEW ARTICLE

Pharmacological MRI (phMRI) of the Human Central Nervous System

H. Lanfermann · C. Schindler · J. Jordan · N. Krug · P. Raab

Drug Development

in Clinical The Journal of Clinical Pharmacology

Usability of Functional MRI in Clinical Studies for Fast and Reliable Assessment of Renal Perfusion and Quantification of Hemodynamic Effects on the Kidney

Tobias Getzin, MD¹*, Marcus May, MD²*, Martina Schmidbauer, MD¹, Marcel Gutberlet, PhD¹, Petros Martirosian, PhD³, Reinhard Oertel, PhD⁴, Frank Wacker, MD¹, Christoph Schindler, MD^{2†}, and Katja Hueper, MD^{1†} Establishment of a cohort for deep phenotyping of the immune response to influenza vaccination among elderly individuals recruited from the general population Manas K. Akmatov, Peggy Riese, Marcus May, Leonhard Jentsch, Malik W. Ahmed, Damaris Werner, Anja Rösel, Megan Tyler, Kevin Pessler, Jana Prokein, Inga Bernemann, Norman Klopp, Blair Prochnow, Stephanie Trittel, Aravind Tallam, Thomas Illig, Christoph Schindler, Carlos A. Guzmán & Frank Pessler

Human Vaccines & Immunotherapeutics

PHASE I STUDIES

uman VACCINES

CrossMark

2017,00(0) 1-7

DOI: 10.1002/jcph.1034

© 2017, The American College of Clinical Pharmacology




Taylor & Francis

Phase lb study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer

Andreas Schneeweiss¹ • Tjoung-Won Park-Simon² • Joan Albanell³ • Ulrik Lassen⁴ • Javier Cortés^{5,6} • Veronique Dieras⁷ • Marcus May² • Christoph Schindler² • Frederik Marmé¹ • Juan Miguel Cejalvo⁸ • Maria Martinez-Garcia³ • Iria Gonzalez³ • Jose Lopez-Martin⁹ • Anja Welt¹⁰ • Christelle Levy¹¹ • Florence Joly¹¹ • Francesca Michielin¹² • Wolfgang Jacob¹³ • • Céline Adessi¹² • Annie Moisan¹² • Georgina Meneses-Lorente¹⁴ • Tomas Racek¹² • Ian James¹⁵ • Maurizio Ceppi¹³ • Max Hasmann¹³ • Martin Weisser¹³ • Andrés Cervantes⁸





Original Paper

Endocannabinoid Modulation Using Monoacylglycerol Lipase Inhibition in Tourette Syndrome: A Phase 1 Randomized, Placebo-Controlled Study



Kirsten R. Müller-Vahl¹⁽¹⁾, Carolin Fremer¹, Chan Beals², Jelena Ivkovic³, Henrik Loft³, Christoph Schindler⁴

Affiliations

Authors

- 1 Department of Psychiatry, Social Psychiatry and Psychotherapy, Hannover Medical School, Hannover, Germany
- 2 Abide Therapeutics, San Diego, CA, USA
- 3 H. Lundbeck A/S, Valby, Denmark
- 4 Clinical Research Center Core Facility, Hannover Medical School, Hannover, Germany.

Key words

Tourette syndrome, endocannabinoid, monoacylglycerol lipase, Lu AG06466

received 13.05.2021 revised 11.10.2021 accepted 12.10.2021 published online 2021

Bibliography

Zentrum für Klinische Studien der MHH Pharmacopsychiatry DOI 10.1055/a-1675-3494 ISSN 0176-3679 © 2021. The Author(s). Supplementary Material is availabe under http://doi.org/10.1055/a-1675-3494

ABSTRACT


Introduction Tourette syndrome (TS) is a complex neurodevelopmental disorder characterized by chronic motor and vocal tics. While consistently effective treatment is lacking, evidence indicates that the modulation of endocannabinoid system is potentially beneficial. Lu AG06466 (previously ABX-1431) is a highly selective inhibitor of monoacylglycerol lipase, the primary enzyme responsible for the degradation of the endocannabinoid ligand 2-arachidonoylglycerol. This exploratory study aimed to determine the effect of Lu AG06466 versus placebo on tics and other symptoms in patients with TS.

9 Thie

Methods In this phase 1b cross-over study, 20 adult patients with TS on standard-of-care medications were randomized to a single fasted dose of Lu AGO6466 (40 mg) or placebo in period 1, followed by the other treatment in period 2. The effects on tics, premonitory urges, and psychiatric comorbidities were evaluated using a variety of scaled approaches at different time points before and after treatment.

Results All scales showed an overall trend of tic reduction,

Pharmacopsychiatry 2022; 55 (3): 148 – 156 PMID: 34847610



CNS

BRIEF REPORT

Monoacylglycerol Lipase Inhibition in Tourette Syndrome: A 12-Week, Randomized, Controlled Study

Kirsten R. Müller-Vahl, MD,^{1*} Carolin Fremer, MSc,¹ Chan Beals, MD,² Jelena Ivkovic, MD,³ Henrik Loft, MSc, PhD,³ and Christoph Schindler, MD⁴ D

¹Department of Psychiatry, Social Psychiatry and Psychotherapy, Hannover Medical School, Hannover, Germany ²Abide Therapeutics, San Diego, California, USA ³H. Lundbeck A/S, Valby, Denmark ⁴Clinical Research Center Core Facility, Hannover Medical School, Hannover, Germany

ABSTRACT: Background: Modulation of the endocannabinoid system via monoacylglycerol lipase inhibition with Lu AG06466 (formerly known as ABX-1431) has previously been shown to reduce tics in patients with Tourette syndrome.

Objective: The aim of this study was to evaluate the efficacy and safety of Lu AG06466 in reducing tics, premonitory urges, and comorbidities in patients with Tourette syndrome.

Methods: This was a 12-week, multicenter, randomized, placebo-controlled, double-blind clinical trial of Lu AG06466 given at two dose levels in 49 adults with Tourette syndrome.

Results: Both treatment groups showed improvement on the Total Tic Score of the Yale Global Tic Severity Scale; the mean (95% CI) treatment difference at week 8 of 3.0 (0.1, 5.9) (P = 0.043) favored placebo. No significant differences were seen for other endpoints assessing changes in tic severity, premonitory urges, quality of life, and common psychiatric



comorbidities. Treatment with Lu-AG06466 was generally safe.

Conclusions: There was no evidence that Lu AG06466 has efficacy in suppressing tics. © 2021 The Authors. *Movement Disorders* published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society

Key Words: tics; Tourette syndrome; Lu AG06466; ABX-1431; endocannabinoid modulator


Tourette syndrome (TS) is a chronic, childhood-onset neurodevelopmental disorder characterized by motor and vocal tics often associated with a spectrum of psychiatric disorders. Although the neurobiological basis of TS remains unclear, most evidence supports an involvement of cortico-striato-thalamo-cortical circuits.¹ In addition to dopaminergic dysfunction,^{2,3} several other neurotransmitters are likely involved. including the endocannabinoid system,4 which, in turn, has a complex functional interaction with the dopaminergic system.5 Hitherto, the role of the endocannabinoid system in TS has been supported by accumulating clinical evidence suggesting that cannabis-based medicines. including Δ9-tetrahydrocannabinol (THC), act as agonists at central cannabinoid CB1 receptors6 to reduce tics and comorbid symptoms.⁷⁻¹¹ In addition, alterations of cerebrospinal fluid levels of the endogenous ligands (endocannabinoids) have been found.12

We have previously reported the results of a singledose phase 1b study that indicated that the monoacylglycerol lipase (MAGL) inhibitor Lu AG06466 (previously known as ABX-1431) reduces tics and pre-

Mov Disord 2021 Jun 12. doi: 10.1002/mds.28681. Online ahead of print.

Received: 24 February 2021; Revised: 27 April 2021; Accepted: 24 May 2021

Published online in Wiley Online Library (wileyonlinelibrary.com). DOI: 10.1002/mds.28681



CNS

Publications Translation ZKS – ECTU 2022


- Lancet Digital Health 2022 (MHH IIT at CRC, CRO Services of ZKS) —
- **Nature Communications 2022** (MHH IIT at CRC with HZI Braunschweig) ___
- Clinical Infectious Diseases 2022 (Industry Research at CRC, ZKS ECTU) _

Predictive performance and clinical application of COV50, ۵. a urinary proteomic biomarker in early COVID-19 infection: a prospective multicentre cohort study

Jan A Staessen*, Ralph Wendt*, Yu J ing Yu, Swen Kalhitz, Lutaarde Thiis, Justwag Siwu, Julia Road, Jachen Metzger, Razhang Neuhaus oa Armin Papkalla, Heiko von dar Leyen, Alexandre Mebazaa, Emmanuel Dudoignon, Goce Spasovski, Mimaza Milenkova, Aleksandra Canevska-Taneska, Mercedes Salqueira Lazo, Mina Psichoqiou, Marek W Rajzer, Eukasz Fuławka, Maqdalena Dzitkowska-Zabielska, Guenter Welss, Torsten Feldt, Miriam Stegemann, Johan Normark, Alexander Zoufaly, Stefan Schmiedel, Michael Seilmaier, Benedikt Rump Mirosiaw Banasik, Maadalena Kralewska, Larenza Catanese, Harald D.Rummerht, Beata Coerwierfska, Biörn Peters, Åsa Nilsson, Katia Bathfuss Christoph Lübbert, Harald Mischak†, Joachim Beiget, on behalf of the CRIT-CoV-U investigators‡

Summary
Background The SARS-GoV-2 pandemic is a worldwide challenge. The CRIT-GoV-U pilot study generated a urinary
Lowst EightMeth2022 proteomic biomarker consisting of 50 peptides (COV50), which predicted death and disease progression from Polabled online SARS-CoV-2. After the interim analysis presented for the German Government, here, we aimed to analyse the full August 31 2022 dataset to consolidate the findings and propose potential clinical applications of this biomarker. https://doi.org/10.1016/ \$2589-7500(22)00150-9

joint first authors who Methods CRIT-CoV-U was a prospective multicentre cohort study. In eight European countries (Austria, France, contributed equally followed up for death and progression along the 8-point WHO scale. Capillary electrophoresis coupled with mass spectrometry was used for urinary proteomic profiling. Statistical methods included logistic regression and receiver ‡CRT-CeV-U investiga operating characteristic curve analysis with a comparison of the new under curve RUC between nexted models. Hospitalisation costs were derived from the care faulty corresponding with the Markov chain probability of renting material transmissions and the care faulty corresponding to the second second



Peggy Riese @^{1,17}, Stephanie Trittel @^{1,17}, Manas K. Akmatov^{2,3}, Marcus May @⁴, Received: 20 October 2021 Jana Prokein⁵, Thomas Illin⁵, Christoph Schindler⁴, Biroit Sawitzki (16⁶⁷) Accepted: 26 October 2022 Yasin Elfaki [©], Stefan Floess [©], Jochen Huehn [©]⁸, Adrian J. Blażejewski¹⁰, Till Strowig ^{2,9,30,11}, Esteban A. Hernandez-Vargas², Robert Ceffers [©]³, Bowen Zhang^{14,5}, Yang Li [©]^{14,5,56}, Frank Pessler^{2,17} & Carlos A. Guzmán^{1,17} Published online: 12 November 2022 Check for updates

nature communications

Articles

Seasonal influenza outbreaks, especially in high-risk groups such as the elderly represent an important public health problem. Prevailing inadequate efficacy of seasonal vaccines is a crucial bottleneck. Understanding the immunologica and molecular mechanisms underpinning differential influenza vaccine responsiveness is essential to improve vaccination strategies. Here we sho comprehensive characterization of the immune response of randomly selected elderly participants (≥ 65 years), immunized with the adjuvanted influenza vaccine Fluad. In-depth analyses by serology, multi-parametric flow cytometry multiplex and transcriptome analysis, coupled to bioinformatics and mathe matical modelling, reveal distinguishing immunological and molecular features between responders and non-responders defined by vaccine-induced seroconversion. Non-responders are specifically characterized by multiple suppressive immune mechanisms. The generated comprehensive high dimensional dataset enables the identification of putative mechanisms and nodes responsible for vaccine non-responsiveness independently of confounding age-related effects, with the potential to facilitate development of

tailored vaccination strategies for the elderly.

Clinical Infectious Diseases MAJOR ARTICLE



VPM1002 as Prophylaxis Against Severe Respiratory Tract Infections Including Coronavirus Disease 2019 in the Elderly: A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Study


Alexandra M. Blossey, ^{La} Sina Brückner, ^{La} Marcus May,¹ Gerald P. Parzmair,¹ Hitt Sharma,² Umesh Shaligram,² Leander Grode,¹ Stefan H. E. Kaufmann,^{34,1} Mihai G. Netea, 47.8 and Christoph Schindler^{9,10}

Vakrine Projekt Management GmbH, Hannover, Germany, ²Serum Institute of India Private Limited, Pune, India; ³Max Planck Institute for Infaction Biology, Berlin, Germany, ⁴Hagler Institute for Advanced Study, Tease ABM University, College Station, Tease, USA: "Maa Planck Institute for Multidisciplinary Sciences, Bittingen, Germany, [®]Department of Internal Mulcione, Redboud University Medical Center, Njimegen, The Netherlands, [®]Redboud Center for Intercious Diseases, Redboud University Medical Center, Njimegen, The Netherlands, [®]Department for Immunology and Metabolism, Life and Medical Sciences. Institute, University of Bonn, Bonn, Germany, "Dinical Research Center Core Facility, Hannover Medical School, Hannover, Germany, and "Center for Pharmacology and Toxicology, Hannover Medical School, Hannover, Germany

Background. Bacille Calmette-Guérin (BCG) vaccination can potentially reduce the rate of respiratory infections in vulnerable populations. This study evaluates the safety and efficacy of VPM1002 (a genetically modified BCG) as prophylaxis against severe respiratory tract infections including coronavirus disease 2019 (COVID-19) in an elderly population

Methods. In this phase 3, randomized, double-blind, placebo-controlled, multicenter clinical trial, healthy elderly volunteers (N = 2064) were enrolled, randomized (1:1) to receive either VPM1002 or placebo, and followed up remotely for 240 days. The primary outcome was the mean number of days with severe respiratory infections at hospital and/or at home. Secondary endpoints included the incidence of self-reported fever, number of hospital and intensive care unit (ICU) admissions, and number of adverse events.





Investigator Initiated Trial



Vaccination

Study Protocol

Study Title:

Safety, reactogenicity and immunogenicity of a novel MVA-SARS-2-ST vaccine

candidate administered as inhalation boost in SARS-CoV-2 immunized adults -

phase I Study



MHH as Central Spider in Research Network of Northern Germany

